

CDRC – Clinical Digital Resource Collaborative

Jody Nichols and Dr Tom Zamoyski

CDRC Implementation Team

Academic Health Science Network for the North East and North Cumbria (AHSN NENC)









Overview

- CDRC Precision What, Who, Why
- Accessing the resources
- Roadmap
- Initial Insights
- Any Questions







What is CDRC

CDRC Precision is an NHS owned fully funded digital resource that supports individuals and organisations to deliver gold-standard patient care efficiently.



Vision

Develop free at the point of use, hazardreviewed digital resources created by clinicians.

Our Vision

Create resources for SystmOne and EMIS

Prevent clinical teams across the country having to reinvent the wheel via creation of a central repository of ICP/ICS/National resources (with regional adaptation where required).



Overview of CDRC Precision

Intuitive templates containing relevant contextual information

Safety-critical alerts/pop-ups & patient status icons


Types of resources available

Powerful searches/reports

Standardised regional letters/referral documents containing relevant merged clinical information



Who's it for?







Dr Gareth ForbesCo-Founder



Dr Jonathan HarnessCo – Founder and Chair



Billie Moyle
Primary Care Data
Quality Lead (NECS)



Kathryn Muckles
Primary Care Data
Quality Specialist (NECS)



I-Lin Hall
CDRC position — CDRC
Delivery Insight (NECS)



Professor Julia Newton Medical Director AHSN



Jody Nichols Implementation Lead (AHSN)



Dr Tom ZamoyskiGP Clinical Lead
(AHSN)



Dr Andrew Richardson GP – EMIS Resource Development Lead (AHSN)



Michelle Waugh
Project Support Officer
(AHSN)



Jordan Hewitt Social media & website lead.



Joanne Dolezal / Sarah Bowman Marketing/Comms & Stakeholder Engagement Experts (AHSN)







Wider Key Partners

- CCGs regionally in NENC (reps from 8 regional CCGs)
- CBC Health (federation)
- Northern Cancer alliance
- Sunderland GP alliance





Benefits

Improved quality and safety for patients, clinicians and the NHS

• by identifying patients who are undiagnosed, misdiagnosed or coded incorrectly.

Improved time / cost savings

• by utilising pre-designed, validated resources (templates, searches, protocols, alerts).

Flexible implementation

• Clinical teams can choose to use only the resources which are important to them.

Safe and compliant data sharing

Improved performance management

• Via the use of 'dashboard' suites of searches/reports which provide real-time data on many aspects of clinical performance.

Opportunity to increase practice income

• By using real-time data/targeted search strategies to support practices to improve their QoF performance.








Accessing The Resources

- Straightforward.
- Different approach EMIS
 vs S1 due to limitations
 with Resource Publisher
 rollout.
- Training materials / guides available





Development Process

Comms created and External / Internal work Training materials / guides organised with Jira distributed via Social (Atlassian) Media/Mailing List/Website Jira Software Jira Service Desk Fortnightly operation 'Huddle' Feedback requested and Prioritise backlog Testing of resources incorporated into resources Identify problems/bottlenecks **North East Commissioning** Support Unit (NECS) Liaising/Collaboration with Hazard Review key partners/networks on •Reciprocal Resource creation active projects (EMIS/SystmOne) necs

Steering Group Meeting

Update to key partners and Strategic/Risk management discussions

Engagement Group Meeting

Marketing / Stakeholder Engagement specialists supporting team to build an appropriate strategy





Resources we've created so far...

- Covid-19 support
- Lipids / FH / PCSK9i
- Atrial Fibrillation
- NEWS2

Priorities and planning of work...






Development Roadmap

- BeatAsthma+
- Year of Care
- Learning Disability support for QOF 20-21
- Asthma LTC
- Diabetes LTC
- Comprehensive Geriatric Assessment
- Meds Management System






Resources for CVD Prevention




Lipid Management Templates



FH Searches



Lipid Searches




PCSK9i Searches





Lipid Templates



Lipid Searches

CVD Prevention - Diabetes06b - Eligible for Diabetes Assessment - High risk ethnicity >25y/BMI>23 OR Actual DMUK >=16 and n		0.0 %
CVD Prevention - Lipids01 - Manifest atherosclerosis		6.2 %
CVD Prevention - Lipids01a - Manifest atherosclerosis on very high intensity lipid lowering		21.4 %
CVD Prevention - Lipids01b - Manifest atherosclerosis on high/very high intensity lipid lowering		67.9 %
CVD Prevention - Lipids01c - Manifest atherosclerosis on high/very high intensity statin OR On low/mod intensity lipid lowering A		74.1 %
CVD Prevention - Lipids01d - Manifest atherosclerosis on lipid lowering		88.8 %
CVD Prevention - Lipids01e - Manifest atherosclerosis on lipid lowering OR Reason why not		93.0 %
CVD Prevention - Lipids02 - Possible Missed Manifest atherosclerosis		0.0 %
CVD Prevention - Lipids03 - FH - definite, possibe or probable		0.5 %
CVD Prevention - Lipids03a - FH on very high intensity lipid lowering		18.8 %
CVD Prevention - Lipids03b - FH on high intensity lipid lowering		68.8 %
CVD Prevention - Lipids03c - FH - on high/very high intensity statin OR On low/mod intensity lipid lowering AND Atorvastatin ADR	27	84.4 %
CVD Prevention - Lipids03d - FH on lipid lowering	31	96.9 %
CVD Prevention - Lipids03e - FH on lipid lowering OR reason why not	31	96.9 %
CVD Prevention - Lipids03f - FH Case Finding - Raised cholesterol without diagnosis of FH (TC 9/7.5)	28	0.5 %
CVD Prevention - Lipids03g - FH Case Finding - Raised cholesterol without diagnosis of FH (TC 7.5 AND PHx/FHx prem CHD)	83	1.4 %
CVD Prevention - Lipids05 - Primary Prevention Indicated	1154	19.1 %
CVD Prevention - Lipids05a - Primary Prevention - on very high intensity lipid lowering	6	0.5 %
CVD Prevention - Lipids05b - Primary Prevention - on high intensity lipid lowering	538	46.6 %
CVD Prevention - Lipids05c - Primary Prevention - on high/very high intensity statin OR On low/mod intensity lipid lowering AND A	573	49.7 %
CVD Prevention - Lipids05d - Primary Prevention - on lipid lowering	697	60.4 %
CVD Prevention - Lipids05di - Primary Prevention - on lipid lowering - not issued in last 3 months	44	6.3 %
CVD Prevention - Lipids05e - Primary Prevention - on lipid lowering OR reason why not	811	70.3 %
CVD Prevention - Lipids05f - Primary Prevention - NOT on lipid lowering NOR reason why not	346	30.1 %
CVD Prevention - Lipids05f - Primary Prevention - NOT on lipid lowering NOR reason why not - due NHS HC	55	0.9 %
CVD Prevention - Lipids05f - Primary Prevention - NOT on lipid lowering NOR reason why not - due NHS HC (ever)	109	1.8 %
CVD Prevention - Lipids06 - Assess CVD Risk - estimated risk >=10%	137	2.3 %
CVD Prevention - Lipids06a - Assess CVD Risk - on very high intensity lipid lowering	0	0.0 %
CVD Prevention - Lipids06b - Assess CVD Risk - on high intensity lipid lowering	0	0.0 %
CVD Prevention - Lipids06c - Assess CVD Risk - on high/very high intensity statin OR On low/mod intensity lipid lowering AND At	0	0.0 %
CVD Prevention - Lipids06d - Assess CVD Risk - on lipid lowering	0	0.0 %
CVD Prevention - Lipids06e - Assess CVD Risk - on lipid lowering OR reason why not	0	0.0 %
CVD Prevention - Lipids06f - Assess CVD Risk - not on lipid lowering NOR reason why not	137	100.0 %
CVD Prevention - Lipids06f - Assess CVD Risk - not on lipid lowering NOR reason why not - due NHS HC		0.9 %
CVD Prevention - Lipids06f - Assess CVD Risk - not on lipid lowering NOR reason why not - due NHS HC (ever)	98	1.6 %
CVD Prevention - Overtreatment - >2 diabetes drugs and Hb1c <48		

FH Searches - Development

Collaboration with regional lipid specialists comparing FH detection tools: NICE, Simon Broome, DLCNS, and FAMCAT


Searches refined to improve accuracy: adding LDL and non-HDL criteria to the NICE criteria, adjusting for high triglycerides (>2.3)

Identified patients were then reviewed by Specialist Lipid Nurses to decide who required further assessment and/or genetic testing. This information was used to develop search strategies which can adjust sensitivity and specificity.



FH Search Strategy for National Programme

CDRC Supporting Clinical Decisions



ct-CDRC@ahsn-nenc.org.uk

PCSK9i Searches - Development

Search strategy based on NICE guidance (Evolocumab - Technology appraisal guidance [TA394])

Development of additional 'filter' searches to support the process of identifying patients most likely to be eligible.







PCSK9i Search Strategy

Clinical Digital Resource Collaborative

Join our Journey

CDRC Supporting Clinical Decisions

North East and North Cumbria

OR

CDRC PCSK9i referral search criteria:

Diagnosed FH

AND

LDL-C > 5

OR

Diagnosed FH and CHD or PAD or Stroke* or TIA

AND

LDL-C > 3.5

OR

At least two of: CHD, PAD, Stroke*. TIA OR recurrent ACS or Stroke* or TIA

AND

LDL-C > 3.5

CHD or PAD or Stroke* or TIA

AND

LDL-C > 4.0**

or

Non-HDL > 5.0**

or

Total Cholesterol > 6.0**

Additional searches: these are filters of the main search (left) to help with the screening process.

Core PCSK9i Search

Excluding

Palliative Care or Moderate/Severe Frailty

Core PCSK9i Search

Excluding

Patients prescribed lipid lowering therapy which has not been issued within the last 3 months

(this search helps to exlude patients with high lipids due to non-concordance)

Core PCSK9i Search

AND

Patients who have already tried both a Statin and Ezetimibe

cdrc.nhs.uk



Join our Journey

CDRC Supporting Clinical Decisions




contact-CDRC@ahsn-nenc.org.uk


^{*} non-haemorrhagic stroke

^{**}result obtained at least 9 months following diagnosis

Initial Request Insights (non-exhaustive)









Some other points...

- What about Gareth Forbes' DCS system?
- Support: Jargon-free knowledge-base is direction of travel
- Regional pathways/guidelines Please involve CDRC early







Any Questions?

contact-CDRC@ahsn-nenc.org.uk

Thank you



